As congressional lawmakers continue efforts to lower drug prices, U.S. Representative Elijah Cummings (D-MD), who chairs the House Oversight and Government Reform Committee, launched an investigation into price-gouging. He sent letters to 12 drug makers (AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi, and Teva Pharmaceuticals) seeking information about pricing practices.
The missive also asked for information about investments in research and development, which are often used to justify high drug prices.
Rep. Cummings’ letters focused on drugs costliest to Medicare Part D and drugs that have had the largest price increases over five years, including adalimumab, lenalidomide, and ibrutinib.
Source: Reuters, January 14, 2019.